{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T02:53:44Z","timestamp":1763866424128,"version":"3.45.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017591","name":"Key Industry Innovation Chain of Shaanxi","doi-asserted-by":"publisher","award":["2018TD-002"],"award-info":[{"award-number":["2018TD-002"]}],"id":[{"id":"10.13039\/501100017591","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81272488","81602802","82373204"],"award-info":[{"award-number":["81272488","81602802","82373204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jare.2025.02.042","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T11:32:04Z","timestamp":1741001524000},"page":"793-806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cracking melanoma\u2019s armor: Supramolecular dual-strike on XPO1 and \u03b2-catenin to overcome resistance"],"prefix":"10.1016","volume":"77","author":[{"given":"Yinliang","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruishan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanmin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wangxiao","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suxia","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2025.02.042_b0005","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nature05985","article-title":"The common biology of cancer and ageing","volume":"448","author":"Finkel","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jare.2025.02.042_b0010","doi-asserted-by":"crossref","unstructured":"Weinberg RA, Weinberg RA. The biology of cancer, WW Norton & Company; 2006","DOI":"10.1201\/9780203852569"},{"key":"10.1016\/j.jare.2025.02.042_b0015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/1523-1747.ep12343580","article-title":"Increased nuclear volume in metastasizing \u201cThick\u201d melanomas","volume":"106","author":"Mossbacher","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jare.2025.02.042_b0020","first-page":"646","article-title":"Intralesional and metastatic heterogeneity in malignant melanomas demonstrated by stereologic estimates of nuclear volume, Laboratory investigation","volume":"62","author":"S\u00f8rensen","year":"1990","journal-title":"J Tech Meth Pathol"},{"key":"10.1016\/j.jare.2025.02.042_b0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","article-title":"Nucleo-cytoplasmic transport as a therapeutic target of cancer","volume":"7","author":"Gravina","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jare.2025.02.042_b0030","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1016\/j.bbamcr.2014.08.003","article-title":"Macromolecular transport between the nucleus and the cytoplasm: advances in mechanism and emerging links to disease","volume":"1843","author":"Tran","year":"2014","journal-title":"Biochim Biophy Acta (BBA) \u2013 Mol Cell Res"},{"key":"10.1016\/j.jare.2025.02.042_b0035","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0092-8674(00)80371-2","article-title":"CRM1 is an export receptor for leucine-rich nuclear export signals","volume":"90","author":"Fornerod","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.jare.2025.02.042_b0040","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2014.03.002","article-title":"Atomic basis of CRM1-cargo recognition, release and inhibition","volume":"27","author":"Fung","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jare.2025.02.042_b0045","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/JID.2015.401","article-title":"RanBP3 regulates melanoma cell proliferation via selective control of nuclear export","volume":"136","author":"Pathria","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jare.2025.02.042_b0050","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1038\/jid.2012.233","article-title":"Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways","volume":"132","author":"Pathria","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jare.2025.02.042_b0055","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/ijc.24146","article-title":"The Karyopherin proteins, Crm1 and Karyopherin \u03b21, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation","volume":"124","author":"van der Watt","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jare.2025.02.042_b0060","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/jcmm.17667","article-title":"Protein biomarkers for response to XPO1 inhibition in haematologic malignancies","volume":"27","author":"Totiger","year":"2023","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jare.2025.02.042_b0065","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s00432-022-04247-z","article-title":"The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review","volume":"149","author":"Landes","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jare.2025.02.042_b0070","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1 - from biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jare.2025.02.042_b0075","doi-asserted-by":"crossref","unstructured":"Naing A, Fu S, Tsimberidou AM, Pant S, Piha-Paul SA, Janku F, et al. Phase IB study to evaluate the safety of selinexor in combination with multiple standard chemotherapy agents in patients with advanced malignancies 2017;35 (2017):TPS2603\u2013TPS2603.","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS2603"},{"key":"10.1016\/j.jare.2025.02.042_b0080","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-016-0304-z","article-title":"Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors","volume":"9","author":"Turner","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jare.2025.02.042_b0085","doi-asserted-by":"crossref","first-page":"10402","DOI":"10.1073\/pnas.1903506116","article-title":"Wnt canonical pathway activates macropinocytosis and lysosomal degradation of extracellular proteins","volume":"116","author":"Tejeda-Mu\u00f1oz","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jare.2025.02.042_b0090","doi-asserted-by":"crossref","first-page":"45091","DOI":"10.1074\/jbc.M207439200","article-title":"Docking of HIV-1 Vpr to the nuclear envelope is mediated by the interaction with the nucleoporin hCG1","volume":"277","author":"Le Rouzic","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jare.2025.02.042_b0095","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1091\/mbc.e04-11-0998","article-title":"Interaction between the shuttling mRNA export factor Gle1 and the nucleoporin hCG1: a conserved mechanism in the export of Hsp70 mRNA","volume":"16","author":"Kendirgi","year":"2005","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.jare.2025.02.042_b0100","first-page":"1","article-title":"Effect of HER2 expression on NUPL2 protein in cervical cancer effect of HER2 expression on NUPL2 protein in cervical cancer cells","author":"Mary","year":"2021","journal-title":"Kentucky J Undergrad Scholarship"},{"issue":"2023","key":"10.1016\/j.jare.2025.02.042_b0105","doi-asserted-by":"crossref","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.jare.2025.02.042_b0110","first-page":"54","article-title":"Exploiting cancer's drinking problem: regulation and therapeutic potential of macropinocytosis, Trends","volume":"8","author":"Puccini","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.jare.2025.02.042_b0115","doi-asserted-by":"crossref","first-page":"D338","DOI":"10.1093\/nar\/gks936","article-title":"ValidNESs: a database of validated leucine-rich nuclear export signals","volume":"41","author":"Fu","year":"2013","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.jare.2025.02.042_b0120","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0092-8674(00)80370-0","article-title":"Exportin 1 (Crm1p) is an essential nuclear export factor","volume":"90","author":"Stade","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.jare.2025.02.042_b0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-020-00903-4","article-title":"XPO1-dependent nuclear export as a target for cancer therapy","volume":"13","author":"Azizian","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jare.2025.02.042_b0130","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.11466","article-title":"A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning","volume":"4","author":"K\u0131rl\u0131","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.jare.2025.02.042_b0135","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1038\/jid.2012.233","article-title":"Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways","volume":"132","author":"Pathria","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jare.2025.02.042_b0140","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1746-6148-10-160","article-title":"Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines","volume":"10","author":"Breit","year":"2014","journal-title":"BMC Vet Res"},{"key":"10.1016\/j.jare.2025.02.042_b0145","article-title":"Novel small molecule XPO1\/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells","volume":"9","author":"Yang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jare.2025.02.042_b0150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature03664","article-title":"Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma","volume":"436","author":"Garraway","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jare.2025.02.042_b0155","doi-asserted-by":"crossref","first-page":"E8668","DOI":"10.1073\/pnas.1810498115","article-title":"BRAF\/MAPK and GSK3 signaling converges to control MITF nuclear export","volume":"115","author":"Ngeow","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jare.2025.02.042_b0160","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jamcollsurg.2017.12.040","article-title":"Prognostic role of BRAF(V600E) cellular localization in melanoma","volume":"226","author":"Abd Elmageed","year":"2018","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jare.2025.02.042_b0165","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2025.02.042_b0170","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jare.2025.02.042_b0175","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors","volume":"34","author":"Abdul Razak","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2025.02.042_b0180","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/bjc.1996.415","article-title":"Phase I trial of elactocin","volume":"74","author":"Newlands","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jare.2025.02.042_b0185","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3389\/fphar.2020.00625","article-title":"Small Molecule Inhibitors of CRM1","volume":"11","author":"Ferreira","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jare.2025.02.042_b0190","doi-asserted-by":"crossref","first-page":"15534","DOI":"10.1021\/acs.jmedchem.1c01145","article-title":"Chromosome region maintenance 1 (XPO1\/CRM1) as an anticancer target and discovery of its inhibitor","volume":"64","author":"Liu","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.jare.2025.02.042_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/genes11080886","article-title":"Nuclear regulation of Wnt\/\u03b2-catenin signaling: it's a complex situation","volume":"11","author":"Anthony","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jare.2025.02.042_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2016.06.009","article-title":"Wnt\/\u03b2-catenin signaling in melanoma: preclinical rationale and novel therapeutic insights","volume":"49","author":"Xue","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jare.2025.02.042_b0205","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jare.2025.02.042_b0210","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bcp.2017.02.011","article-title":"USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth","volume":"131","author":"An","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jare.2025.02.042_b0215","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/med.21787","article-title":"Direct targeting of \u03b2-catenin in the Wnt signaling pathway: Current progress and perspectives","volume":"41","author":"Wang","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.jare.2025.02.042_b0220","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/ncomms1680","article-title":"An intrinsically labile \u03b1-helix abutting the BCL9-binding site of \u03b2-catenin is required for its inhibition by carnosic acid","volume":"3","author":"de la Roche","year":"2012","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2025.02.042_b0225","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7150\/ijbs.66612","article-title":"Verdinexor, a selective inhibitor of nuclear exportin 1, inhibits the proliferation and migration of esophageal cancer via XPO1\/c-Myc\/FOSL1 axis","volume":"18","author":"Ou","year":"2022","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.jare.2025.02.042_b0230","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.18632\/oncotarget.1813","article-title":"Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer","volume":"5","author":"Gao","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.jare.2025.02.042_b0235","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1128\/JVI.79.2.1339-1341.2005","article-title":"A tumor cell-specific nuclear targeting signal within chicken anemia virus VP3\/apoptin","volume":"79","author":"Poon","year":"2005","journal-title":"J Virol"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225001419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225001419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T02:20:16Z","timestamp":1763864416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123225001419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":47,"alternative-id":["S2090123225001419"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2025.02.042","relation":{},"ISSN":["2090-1232"],"issn-type":[{"type":"print","value":"2090-1232"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cracking melanoma\u2019s armor: Supramolecular dual-strike on XPO1 and \u03b2-catenin to overcome resistance","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2025.02.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}